GRC 65327
Alternative Names: GRC-65327Latest Information Update: 08 Nov 2024
Price :
$50 *
At a glance
- Originator Ichnos Glenmark Innovation
- Developer Ichnos Glenmark Innovation; National Cancer Institute (USA)
- Class Antineoplastics; Small molecules
- Mechanism of Action CBLB protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Triple negative breast cancer
Most Recent Events
- 30 Sep 2024 Ichnos Glenmark Innovation entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute on evaluating GRC 65327
- 30 Sep 2024 Preclinical trials in Triple-negative-breast-cancer in USA (PO)
- 30 Sep 2024 Ichnos Glenmark Innovation plans a clinical trial for Solid tumours (Second-line therapy or greater) in early 2025